Zepbound vs Wegovy: which suits whom?
The short answer
Zepbound vs Wegovy is a choice between tirzepatide from Eli Lilly and semaglutide from Novo Nordisk, both FDA-approved for long-term weight reduction. Wegovy also has cardiovascular and MASH uses and a tablet. Zepbound also covers obstructive sleep apnea. Self-pay maintenance costs $349 a month for the Wegovy 2.4 mg pen and $449 for Zepbound vials at 7.5 mg and above.
Key takeaways
- The trials were run separately, so their weight results can't be ranked against each other.
- Only Wegovy's label has a cardiovascular use. Only Zepbound's has an obstructive sleep apnea use.
- Want a tablet? Wegovy has one. Zepbound comes only as an injection.
- Paying cash? The Wegovy 2.4 mg pen is $349 a month. Zepbound from 7.5 mg up is $449 with on-time refills.
- The two aren't used together, and no label converts one dose into the other. Your prescriber decides how you move.
On this page
Wegovy vs Zepbound, side by side
| Wegovy | Zepbound | |
|---|---|---|
| Active ingredient | semaglutide | tirzepatide |
| Maker | Novo Nordisk | Eli Lilly and Company |
| FDA-approved uses |
|
|
| How it is taken | weekly (single-dose pen); daily (tablet) | weekly (multi-dose pen); weekly (multi-dose vial); weekly (single-dose pen); weekly (single-dose vial) |
| Strengths | 0.25 to 25 mg | 2.5 to 15 mg |
| Label starting dose |
|
|
| Cheapest verified self-pay | $299 per fill at 25 mg | $449 per fill at 15 mg |
| With covering commercial insurance | $25 with the manufacturer card | $25 with the manufacturer card |
| Medicare GLP-1 Bridge | Yes: Single-dose pen (7.2 mg pen is branded WEGOVY HD); Tablet (once daily) | Yes: KwikPen (multi-dose, 4 weekly doses) |
| Label | Revised: 6/2026 (DailyMed version 19) | Revised: 8/2026 (DailyMed version 40) |
| Reaction | Wegovy injection 2.4 mg once weekly | Placebo |
|---|---|---|
| Nausea | 44% | 16% |
| Diarrhea | 30% | 16% |
| Vomiting | 24% | 6% |
| Constipation | 24% | 11% |
| Abdominal Pain | 20% | 10% |
| Headache | 14% | 10% |
| Reaction | 15 mg | Placebo |
|---|---|---|
| Nausea | 28% | 8% |
| Diarrhea | 23% | 8% |
| Vomiting | 13% | 2% |
| Constipation | 11% | 5% |
| Abdominal Pain | 10% | 5% |
| Dyspepsia | 10% | 4% |
Each table comes from that medicine's own trials. The trials differ in who was studied and for how long, so the percentages are not a head-to-head comparison.
Wegovy and Zepbound are the two once-weekly injections approved in the United States for long-term weight reduction. They’re different molecules from different companies: Wegovy is semaglutide from Novo Nordisk, and Zepbound is tirzepatide from Eli Lilly. Because their main use overlaps, the choice usually comes down to what else is on each label, the form you prefer, what your plan covers, and what each costs on the route open to you.
Which one suits whom?
- You have established cardiovascular disease with obesity or overweight. Wegovy is approved to reduce the risk of major adverse cardiovascular events in that group. Zepbound’s label has no cardiovascular use.
- You have moderate to severe obstructive sleep apnea with obesity. That use is on the Zepbound label only.
- You have MASH with moderate to advanced liver fibrosis. The Wegovy injection is approved for it, under accelerated approval.
- The patient is aged 12 to 17. The Wegovy injection is approved for patients 12 and older with obesity. The safety and effectiveness of Zepbound haven’t been established in children.
- You’d rather take a tablet. Wegovy has one. Zepbound doesn’t.
- You’re paying cash. Compare the dose you expect to stay on. The Wegovy 2.4 mg pen is $349 a month and Wegovy 25 mg tablets are $299. Zepbound vials are $399 at 5 mg and $449 at 10 mg or 15 mg with on-time refills.
- You’re on Medicare. Both are in the Bridge, but for Zepbound only the KwikPen is.
What is each one approved for?
Both are approved to reduce excess body weight and keep it off long term in adults with obesity, or with overweight and at least one weight-related condition. Past that shared use, the labels branch. Wegovy adds cardiovascular risk reduction (injection and tablets), pediatric obesity from age 12 (injection) and MASH (injection). Zepbound adds obstructive sleep apnea.
Each label also rules out using the two together. Wegovy’s says use with any other GLP-1 receptor agonist isn’t recommended, and Zepbound’s says the same of any GLP-1 receptor agonist.
How do the doses and forms compare?
Both injections are given once weekly, at any time of day, with or without meals. The dose ladders have nothing else in common, and a milligram of one is not a milligram of the other.
Wegovy starts at 0.25 mg and rises every 4 weeks through 0.5 mg, 1 mg and 1.7 mg, reaching the usual maintenance dosage (the dose you stay on) of 2.4 mg from week 17. Adults taking it for weight reduction who have tolerated 2.4 mg for at least 4 weeks may be moved to 7.2 mg (Wegovy HD). You inject it in the abdomen, thigh or upper arm.
Zepbound starts at 2.5 mg for 4 weeks, goes to 5 mg, and may then rise in 2.5 mg steps after at least 4 weeks on each dose, to a maximum of 15 mg. The recommended maintenance dosage for weight reduction is 5 mg, 10 mg or 15 mg. You inject it in the abdomen or thigh, or the back of the upper arm if another person gives the injection.
The devices differ too:
- Wegovy single-dose pen. One pen, one dose, used once. A carton holds 4.
- Wegovy tablets. 1.5 mg, 4 mg, 9 mg, 25 mg, once daily in the morning on an empty stomach.
- Zepbound single-dose vial. Drawn up with a syringe. The label says to use a new syringe and needle for each injection.
- Zepbound KwikPen. One pen holding four weekly doses.
The dosing guide sets the two ladders out step by step, and the pen vs vial vs pill comparer prices the forms of each drug.
What does each label report on weight?
Each label reports placebo-controlled trials of its own drug, so the figures below are two separate findings, not a comparison.
- Wegovy. In Study 2, a 68-week trial in adults with obesity or overweight and without diabetes, mean (average) body-weight change was -14.9% with the 2.4 mg injection versus -2.4% with placebo.
- Zepbound. In Study 1, in adults without diabetes, weight was assessed after 72 weeks. Mean change was -15.0% with 5 mg, -19.5% with 10 mg and -20.9% with 15 mg, versus -3.1% with placebo.
The trials differ in length, dose design and participants. Results also shift within a label: Wegovy’s says the injection produced less weight reduction in people with type 2 diabetes. These are averages for a trial group. They aren’t a forecast for one person, and they don’t rank the two medicines.
What does each one cost?
On each company’s self-pay program:
Wegovy (NovoCare). New patients pay $199 a month for up to two fills of 0.25 mg or 0.5 mg, then $349. The 1 mg, 1.7 mg and 2.4 mg pens are $349 a month and the 7.2 mg pen is $399. Tablets are $149 for 1.5 mg, $199 for 4 mg and $299 for 9 mg and 25 mg.
Zepbound (LillyDirect). Vials and the KwikPen are $299 a month at 2.5 mg, $399 at 5 mg and $449 at 7.5 mg to 15 mg. From 7.5 mg up, you get that price only if you buy each refill within 45 days of getting the last one. After that, 10 mg and above cost $699. Wegovy’s self-pay prices have no refill-window rule.
With commercial insurance that covers the drug. The Wegovy savings offer goes as low as $25 a month, and the Zepbound savings card as low as $25 for the single-dose pen.
List price. This is the full price before any discount: $1,349.02 per package for Wegovy and $1,086.37 per fill for the Zepbound single-dose pen.
Your first year, starting at the lowest dose and stepping up on the label’s schedule, comes to $4,237 for Wegovy to 2.4 mg and $5,637 for Zepbound vials to 15 mg. The cost calculator runs the same sum for a different target dose, and the Wegovy cost and Zepbound cost pages rank every route.
How do insurance and Medicare treat them?
Commercial plans. Both fall under weight-management coverage, which some plans exclude. Plans that do cover the class often prefer one brand, so the cheaper medicine for you may simply be the one on your formulary (the plan’s list of covered drugs). Ask which is preferred and what prior authorization (the plan’s approval before it pays) requires. See the insurance guide and the appeal letter generator.
Medicare. CMS says Medicare and Medicaid generally do not cover GLP-1 drugs for the weight loss indication. Each brand has a Part D route for another use: CMS names Wegovy for cardiovascular risk reduction and Zepbound for obstructive sleep apnea as coverable. For weight management, the Medicare GLP-1 Bridge includes both at a $50 copay, with one catch: the Wegovy pen and tablets are covered, but for Zepbound only the KwikPen is. Details are on the Wegovy and Zepbound Medicare pages.
How do the side effects compare?
Both labels have a boxed warning about the risk of thyroid C-cell tumors, and the common reactions on both are gastrointestinal (stomach and bowel). The rates come from separate trial programs. They’re here so you know what each label reports, not to rank the two.
Wegovy. In three placebo-controlled trials in adults with obesity or overweight, on the 2.4 mg injection for up to 68 weeks, nausea was reported by 44 percent of patients (16 percent on placebo), diarrhea by 30 percent (16 percent), vomiting by 24 percent (6 percent) and constipation by 24 percent (11 percent). In these trials, 6.8% of patients on Wegovy and 3.2% on placebo permanently stopped treatment because of adverse reactions.
Zepbound. In the pool of two weight-reduction trials, up to 72 weeks, nausea was reported by 25, 29 and 28 percent of patients on 5 mg, 10 mg and 15 mg (8 percent on placebo), diarrhea by 19, 21 and 23 percent (8 percent), vomiting by 8, 11 and 13 percent (2 percent) and constipation by 17, 14 and 11 percent (5 percent). Across both trials, 4.8%, 6.3% and 6.7% of patients on the three doses permanently stopped treatment because of adverse reactions, versus 3.4% on placebo.
Both labels say gastrointestinal reactions were most frequent during dose escalation, while the dose was going up. The side effects guide covers the warnings on each label.
Switching between Wegovy and Zepbound
People change in either direction for coverage, cost or tolerability reasons. Neither label maps one drug’s dose onto the other’s. The Zepbound label gives no instructions for switching from another GLP-1 medicine and states only its starting dose. The Wegovy label’s switching section is about moving between its own injection and tablets.
What the labels do say is that the two aren’t used at the same time. Your prescriber decides where you start on the new medicine, and how long after the last dose of the old one. Our pages on switching from Wegovy to Zepbound and from Zepbound to Wegovy set out both labels and the change in cost.
Frequently asked questions
Is Zepbound better than Wegovy for weight loss?
Each label reports its own placebo-controlled trials. Wegovy's main trial in adults without diabetes ran 68 weeks, and Zepbound's ran 72 weeks. Different lengths and different participants mean the two sets of results can't be ranked. Your prescriber weighs your history and coverage.
Which is cheaper, Wegovy or Zepbound?
It depends on the dose and form. On self-pay, the Wegovy pen is $349 a month at 1 mg to 2.4 mg, and Zepbound vials or KwikPen are $399 at 5 mg and $449 at 7.5 mg and above when you refill on time. Wegovy tablets are lower, from $149 to $299. With covered commercial insurance, both savings cards go as low as $25.
Wegovy vs Zepbound: what is the difference?
They contain different molecules: Wegovy is semaglutide and Zepbound is tirzepatide. Both are approved for long-term weight reduction in adults. Wegovy's label also covers cardiovascular risk reduction, MASH (injection), patients aged 12 and older with obesity (injection), and a daily tablet. Zepbound's also covers moderate to severe obstructive sleep apnea in adults with obesity.
Can I switch from Wegovy to Zepbound?
A prescriber can switch you, but the Zepbound label gives no instructions for coming from another GLP-1 medicine. It gives only its starting dose, 2.5 mg once weekly. No label converts a Wegovy dose into a Zepbound dose. Both labels say the two shouldn't be used together, so one is stopped before the other is started, on your prescriber's schedule.
Does Medicare cover Wegovy or Zepbound?
Both are in the Medicare GLP-1 Bridge for weight management at a $50 copay for people who qualify: the Wegovy pen and tablets, and the Zepbound KwikPen only. Outside the Bridge, Part D can cover Wegovy for cardiovascular risk reduction and Zepbound for obstructive sleep apnea. Part D doesn't generally cover either for weight loss alone.
Does Wegovy or Zepbound come as a pill?
Wegovy does. Wegovy tablets come in 1.5 mg, 4 mg, 9 mg, 25 mg and are taken once daily in the morning on an empty stomach with up to 4 ounces of water. Zepbound is an injection only, available as a single-dose pen, single-dose vial, multi-dose vial and KwikPen. Lilly's weight-management tablet is a different medicine, Foundayo.
Sources (27)
- 1.FDA label (DailyMed): Wegovy prescribing information, section 1
“Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.”
- 2.FDA label (DailyMed): Zepbound prescribing information, section 1
“ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”
- 3.FDA label (DailyMed): Wegovy prescribing information, section 2.1
“Administer WEGOVY injection once weekly, on the same day each week, at any time of day, with or without meals.”
- 4.FDA label (DailyMed): Zepbound prescribing information, section 2.4
“Administer ZEPBOUND once weekly at any time of day, with or without meals.”
- 5.FDA label (DailyMed): Wegovy prescribing information, section 2.1
“Inject WEGOVY subcutaneously in the abdomen, thigh, or upper arm. The time of day and the injection site can be changed without the need for a dosage modification.”
- 6.FDA label (DailyMed): Zepbound prescribing information, section 2.4
“Inject ZEPBOUND subcutaneously in the abdomen, thigh, or another person should inject in the back of the upper arm. Rotate injection sites with each dose.”
- 7.FDA label (DailyMed): Wegovy prescribing information, Instructions for Use (single-dose pen)
“Your WEGOVY pen is for 1 time use only. The WEGOVY pen is for subcutaneous (under the skin) use only.”
- 8.FDA label (DailyMed): Wegovy prescribing information, section 16
“WEGOVY injection is a clear, colorless solution available in cartons containing 4 single-dose pens, 4 single-dose syringes with integrated needles, or 1 single-patient-use pen (WEGOVY FlexTouch) as follows:”
- 9.FDA label (DailyMed): Zepbound prescribing information, section 2.4
“Instruct patients using ZEPBOUND vials to use a syringe appropriate for dose administration (e.g., a 1 mL syringe capable of measuring a 0.5 mL or 0.6 mL dose) and always use a new syringe and needle for each injection.”
- 10.FDA label (DailyMed): Zepbound prescribing information, section 2.2
“The recommended maintenance dosage is 5 mg, 10 mg, or 15 mg, injected subcutaneously once weekly.”
- 11.FDA label (DailyMed): Zepbound prescribing information, section 2.1
“The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage.”
- 12.FDA label (DailyMed): Wegovy prescribing information, section 2.1
“Take one WEGOVY tablet orally once daily on an empty stomach in the morning with water (up to 4 ounces). Do not take WEGOVY tablets with other liquids besides water”
- 13.FDA label (DailyMed): Wegovy prescribing information, section 14.2, Table 8
“After 68 weeks, treatment with WEGOVY injection resulted in a statistically significant reduction in body weight compared with placebo. Greater proportions of patients treated with WEGOVY injection achieved 5%, 10% and 15% weight loss than those treated with placebo as shown in Table 8.”
- 14.FDA label (DailyMed): Zepbound prescribing information, section 14.1
“In both trials, weight reduction was assessed after 72 weeks of treatment (at least 52 weeks at maintenance dose).”
- 15.FDA label (DailyMed): Zepbound prescribing information, section 14.1, Table 2
“Table 2: Changes in Body Weight at Week 72 in Studies 1 and 2 in Patients with Obesity or Overweight. % Change from baseline: Study 1 Placebo N = 643: -3.1; Study 1 ZEPBOUND 5 mg N = 630: -15.0; Study 1 ZEPBOUND 10 mg N = 636: -19.5; Study 1 ZEPBOUND 15 mg N = 630: -20.9; Study 2 Placebo N = 315: -3.2; Study 2 ZEPBOUND 10 mg N = 312: -12.8; Study 2 ZEPBOUND 15 mg N = 311: -14.7”
- 16.FDA label (DailyMed): Wegovy prescribing information, section 8.6
“Administration of WEGOVY injection resulted in less weight reduction in patients with type 2 diabetes and obesity or overweight compared to those without type 2 diabetes and obesity or overweight”
- 17.FDA label (DailyMed): Zepbound prescribing information, section 8.4
“The safety and effectiveness of ZEPBOUND have not been established in pediatric patients.”
- 18.CMS: Information for Part D Plans
“Beneficiaries who are prescribed an eligible GLP-1 drug for a use that is coverable under the basic Medicare Part D benefit, regardless of whether the eligible GLP-1 drug is on the Part D plan’s formulary (e.g., Zepbound® for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity; Wegovy® to reduce the risk of major adverse cardiovascular (CV) events in adults with established CV disease and either obesity or overweight) would not qualify for coverage of that eligible GLP-1 drug under the Medicare GLP-1 Bridge. Part D plan sponsors must continue to follow their existing formulary exception processes for these requests.”
- 19.CMS: BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model
“GLP-1 drugs for weight loss, along with lifestyle interventions, can help people improve their overall health, but GLP-1s are expensive and currently Medicare and Medicaid generally do not cover these drugs for the weight loss indication.”
- 20.
- 21.
- 22.
- 23.
- 24.
- 25.
- 26.
- 27.
Related pages
- What is Wegovy? Uses, doses, pill and pen, and cost
- What is Zepbound? Uses, cost, doses and side effects
- Wegovy cost: pen and pill prices with and without insurance
- Zepbound cost: what you pay with and without insurance
- Tirzepatide vs semaglutide: how to compare Zepbound, Wegovy, Ozempic and the rest
- Cost calculator
